Workflow
和邦生物: 和邦生物关于控股股东部分股份解除质押及部分股份质押的公告

Core Viewpoint - Sichuan Hebang Biotechnology Co., Ltd. announced the partial release and pledge of shares by its controlling shareholder, Sichuan Hebang Investment Group Co., Ltd., indicating a significant change in the shareholding structure and potential implications for the company's financial stability and investor confidence [1][2][4]. Summary by Sections Share Release Details - Hebang Group released 240,000,000 shares from pledge, accounting for 12.22% of its held shares and 2.72% of the company's total share capital [1][2]. - After the release, the remaining pledged shares amount to 1,069,000,000 shares, which is 54.44% of Hebang Group's total holdings and 12.10% of the company's total share capital [1][2]. Share Pledge Details - The new pledge involves 240,000,000 shares, with the pledge period starting from July 10, 2025, to July 8, 2028, for financing purposes [2][4]. - The pledged shares do not serve as collateral for major asset restructuring or performance compensation [4]. Cumulative Pledge Situation - As of the announcement date, the cumulative pledged shares by Hebang Group and its concerted actor, He Zhenggang, total 1,069,000,000 shares, representing 44.98% of their total holdings and 12.10% of the company's total share capital [1][2][4]. - He Zhenggang holds an additional 412,632,000 shares, which is 4.67% of the company's total share capital [5][6]. Financial Stability and Risk Management - Hebang Group has no shares maturing in the next six months, while 282,000,000 shares are set to mature later, representing 14.36% of their holdings and 3.19% of the company's total share capital, with a corresponding financing balance of 396 million yuan [6]. - The group is expected to manage repayment risks through operational income and dividends, indicating a stable financial outlook [6].